Rockwell Medical, Inc. (RMTI)
USD 0.99
(1.96%)
USD 0.99
(1.96%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 52.17 Million USD | 11.88% |
| 2022 | 46.63 Million USD | -3.99% |
| 2021 | 48.57 Million USD | -37.52% |
| 2020 | 77.74 Million USD | 75.44% |
| 2019 | 44.31 Million USD | -15.68% |
| 2018 | 52.55 Million USD | -10.59% |
| 2017 | 58.77 Million USD | -29.31% |
| 2016 | 83.15 Million USD | -5.32% |
| 2015 | 87.82 Million USD | -10.39% |
| 2014 | 97.99 Million USD | 169.51% |
| 2013 | 36.36 Million USD | 113.58% |
| 2012 | 17.02 Million USD | -46.7% |
| 2011 | 31.93 Million USD | -13.6% |
| 2010 | 36.96 Million USD | 5.99% |
| 2009 | 34.87 Million USD | 83.96% |
| 2008 | 18.95 Million USD | -16.85% |
| 2007 | 22.8 Million USD | 73.37% |
| 2006 | 13.15 Million USD | 42.03% |
| 2005 | 9.26 Million USD | 20.26% |
| 2004 | 7.7 Million USD | 9.31% |
| 2003 | 7.04 Million USD | 9.16% |
| 2002 | 6.45 Million USD | 6.53% |
| 2001 | 6.05 Million USD | 49.51% |
| 2000 | 4.05 Million USD | -9.96% |
| 1999 | 4.5 Million USD | -15.09% |
| 1998 | 5.3 Million USD | 55.88% |
| 1997 | 3.4 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 50.72 Million USD | -2.78% |
| 2024 Q2 | 53.02 Million USD | 4.54% |
| 2023 Q3 | 52.6 Million USD | 38.3% |
| 2023 FY | 52.17 Million USD | 11.88% |
| 2023 Q2 | 38.03 Million USD | -6.02% |
| 2023 Q1 | 40.47 Million USD | -13.22% |
| 2023 Q4 | 52.17 Million USD | -0.82% |
| 2022 FY | 46.63 Million USD | -3.99% |
| 2022 Q3 | 54.18 Million USD | -8.34% |
| 2022 Q1 | 37.43 Million USD | -22.93% |
| 2022 Q2 | 59.11 Million USD | 57.91% |
| 2022 Q4 | 46.63 Million USD | -13.94% |
| 2021 Q1 | 69.44 Million USD | -10.67% |
| 2021 FY | 48.57 Million USD | -37.52% |
| 2021 Q2 | 63.68 Million USD | -8.3% |
| 2021 Q4 | 48.57 Million USD | -17.25% |
| 2021 Q3 | 58.69 Million USD | -7.83% |
| 2020 Q4 | 77.74 Million USD | -8.79% |
| 2020 Q1 | 66.82 Million USD | 50.79% |
| 2020 Q2 | 58.58 Million USD | -12.33% |
| 2020 Q3 | 85.23 Million USD | 45.49% |
| 2020 FY | 77.74 Million USD | 75.44% |
| 2019 FY | 44.31 Million USD | -15.68% |
| 2019 Q3 | 48.08 Million USD | -15.75% |
| 2019 Q2 | 57.07 Million USD | 17.09% |
| 2019 Q4 | 44.31 Million USD | -7.84% |
| 2019 Q1 | 48.74 Million USD | -7.25% |
| 2018 Q4 | 52.55 Million USD | 38.0% |
| 2018 Q1 | 51.95 Million USD | -11.61% |
| 2018 Q2 | 41.41 Million USD | -20.28% |
| 2018 Q3 | 38.08 Million USD | -8.05% |
| 2018 FY | 52.55 Million USD | -10.59% |
| 2017 Q4 | 58.77 Million USD | -10.68% |
| 2017 Q2 | 69.47 Million USD | -13.65% |
| 2017 FY | 58.77 Million USD | -29.31% |
| 2017 Q1 | 80.45 Million USD | -3.24% |
| 2017 Q3 | 65.8 Million USD | -5.28% |
| 2016 Q2 | 87.14 Million USD | -2.19% |
| 2016 Q4 | 83.15 Million USD | 0.36% |
| 2016 FY | 83.15 Million USD | -5.32% |
| 2016 Q3 | 82.85 Million USD | -4.92% |
| 2016 Q1 | 89.09 Million USD | 1.45% |
| 2015 Q4 | 87.82 Million USD | -3.4% |
| 2015 Q1 | 97.16 Million USD | -0.86% |
| 2015 FY | 87.82 Million USD | -10.39% |
| 2015 Q2 | 91.52 Million USD | -5.8% |
| 2015 Q3 | 90.91 Million USD | -0.67% |
| 2014 Q1 | 26.79 Million USD | -26.31% |
| 2014 Q2 | 25.88 Million USD | -3.4% |
| 2014 Q3 | 23.87 Million USD | -7.76% |
| 2014 FY | 97.99 Million USD | 169.51% |
| 2014 Q4 | 97.99 Million USD | 310.52% |
| 2013 Q1 | 17.96 Million USD | 5.54% |
| 2013 Q4 | 36.36 Million USD | -16.6% |
| 2013 Q3 | 43.6 Million USD | -19.3% |
| 2013 FY | 36.36 Million USD | 113.58% |
| 2013 Q2 | 54.02 Million USD | 200.69% |
| 2012 Q1 | 39.42 Million USD | 23.43% |
| 2012 Q4 | 17.02 Million USD | -29.71% |
| 2012 Q3 | 24.22 Million USD | -28.95% |
| 2012 Q2 | 34.09 Million USD | -13.52% |
| 2012 FY | 17.02 Million USD | -46.7% |
| 2011 FY | 31.93 Million USD | -13.6% |
| 2011 Q4 | 31.93 Million USD | -7.66% |
| 2011 Q3 | 34.59 Million USD | 1.43% |
| 2011 Q2 | 34.1 Million USD | -2.26% |
| 2011 Q1 | 34.88 Million USD | -5.62% |
| 2010 FY | 36.96 Million USD | 5.99% |
| 2010 Q2 | 36.82 Million USD | 3.8% |
| 2010 Q1 | 35.48 Million USD | 1.72% |
| 2010 Q3 | 36.22 Million USD | -1.65% |
| 2010 Q4 | 36.96 Million USD | 2.06% |
| 2009 Q3 | 15.83 Million USD | -0.59% |
| 2009 Q1 | 16.06 Million USD | -15.26% |
| 2009 Q2 | 15.93 Million USD | -0.83% |
| 2009 Q4 | 34.87 Million USD | 120.21% |
| 2009 FY | 34.87 Million USD | 83.96% |
| 2008 FY | 18.95 Million USD | -16.85% |
| 2008 Q1 | 22.09 Million USD | -3.08% |
| 2008 Q3 | 21.15 Million USD | -2.78% |
| 2008 Q4 | 18.95 Million USD | -10.39% |
| 2008 Q2 | 21.76 Million USD | -1.52% |
| 2007 Q3 | 12.34 Million USD | 1.18% |
| 2007 FY | 22.8 Million USD | 73.37% |
| 2007 Q1 | 11.91 Million USD | -9.44% |
| 2007 Q2 | 12.2 Million USD | 2.45% |
| 2007 Q4 | 22.8 Million USD | 84.68% |
| 2006 Q3 | 13.59 Million USD | -3.73% |
| 2006 Q4 | 13.15 Million USD | -3.24% |
| 2006 Q1 | 15.18 Million USD | 64.03% |
| 2006 Q2 | 14.12 Million USD | -7.04% |
| 2006 FY | 13.15 Million USD | 42.03% |
| 2005 Q3 | 9.41 Million USD | -3.53% |
| 2005 Q2 | 9.75 Million USD | 1.79% |
| 2005 FY | 9.26 Million USD | 20.26% |
| 2005 Q1 | 9.58 Million USD | 24.47% |
| 2005 Q4 | 9.26 Million USD | -1.61% |
| 2004 Q4 | 7.7 Million USD | 4.65% |
| 2004 Q1 | 7.77 Million USD | 10.38% |
| 2004 Q2 | 7.48 Million USD | -3.75% |
| 2004 Q3 | 7.35 Million USD | -1.69% |
| 2004 FY | 7.7 Million USD | 9.31% |
| 2003 FY | 7.04 Million USD | 9.16% |
| 2003 Q1 | 6.57 Million USD | 1.84% |
| 2003 Q3 | 6.66 Million USD | 4.96% |
| 2003 Q2 | 6.34 Million USD | -3.46% |
| 2003 Q4 | 7.04 Million USD | 5.77% |
| 2002 Q1 | 6.15 Million USD | 1.55% |
| 2002 Q3 | 6.72 Million USD | -1.13% |
| 2002 Q4 | 6.45 Million USD | -4.07% |
| 2002 Q2 | 6.8 Million USD | 10.61% |
| 2002 FY | 6.45 Million USD | 6.53% |
| 2001 Q3 | 4.78 Million USD | 10.6% |
| 2001 Q1 | 4.07 Million USD | 0.67% |
| 2001 FY | 6.05 Million USD | 49.51% |
| 2001 Q4 | 6.05 Million USD | 26.52% |
| 2001 Q2 | 4.32 Million USD | 6.14% |
| 2000 Q3 | 3.84 Million USD | 0.31% |
| 2000 FY | 4.05 Million USD | -9.96% |
| 2000 Q1 | 4.1 Million USD | -8.73% |
| 2000 Q2 | 3.83 Million USD | -6.68% |
| 2000 Q4 | 4.05 Million USD | 5.39% |
| 1999 Q4 | 4.5 Million USD | 4.65% |
| 1999 Q2 | 4.5 Million USD | -8.16% |
| 1999 FY | 4.5 Million USD | -15.09% |
| 1999 Q1 | 4.9 Million USD | -7.55% |
| 1999 Q3 | 4.3 Million USD | -4.44% |
| 1998 Q2 | 5.9 Million USD | -9.23% |
| 1998 Q3 | 5.4 Million USD | -8.47% |
| 1998 Q4 | 5.3 Million USD | -1.85% |
| 1998 FY | 5.3 Million USD | 55.88% |
| 1998 Q1 | 6.5 Million USD | 91.18% |
| 1997 Q3 | 3.6 Million USD | 0.0% |
| 1997 FY | 3.4 Million USD | 0.0% |
| 1997 Q4 | 3.4 Million USD | -5.56% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Journey Medical Corporation | 76.84 Million USD | 32.11% |
| ANI Pharmaceuticals, Inc. | 904.42 Million USD | 94.231% |
| Aquestive Therapeutics, Inc. | 57.41 Million USD | 9.135% |
| Pacira BioSciences, Inc. | 1.57 Billion USD | 96.686% |
| Sunshine Biopharma, Inc. | 27.34 Million USD | -90.782% |
| Sunshine Biopharma, Inc. | 27.34 Million USD | -90.782% |
| SCYNEXIS, Inc. | 128.41 Million USD | 59.371% |
| Safety Shot Inc | 12.7 Million USD | -310.514% |
| Alpha Teknova, Inc. | 128.58 Million USD | 59.426% |
| Collegium Pharmaceutical, Inc. | 1.14 Billion USD | 95.437% |
| Bright Green Corporation | 17.4 Million USD | -199.792% |
| Dynavax Technologies Corporation | 997.09 Million USD | 94.768% |
| Esperion Therapeutics, Inc. | 205.79 Million USD | 74.648% |
| Cosmos Health Inc. | 66.29 Million USD | 21.302% |
| PainReform Ltd. | 9.93 Million USD | -425.408% |
| China SXT Pharmaceuticals, Inc. | 23.12 Million USD | -125.593% |
| Embecta Corp. | 1.21 Billion USD | 95.704% |
| Intra-Cellular Therapies, Inc. | 728.29 Million USD | 92.836% |
| Procaps Group, S.A. | 460.18 Million USD | 88.663% |
| Theratechnologies Inc. | 77.76 Million USD | 32.913% |
| Harrow Health, Inc. | 311.75 Million USD | 83.265% |
| Sonoma Pharmaceuticals, Inc. | 14.89 Million USD | -250.319% |
| Biofrontera Inc. | 27.93 Million USD | -86.786% |
| DURECT Corporation | 45.18 Million USD | -15.455% |
| Supernus Pharmaceuticals, Inc. | 1.4 Billion USD | 96.297% |
| Cronos Group Inc. | 1.13 Billion USD | 95.4% |
| OptiNose, Inc. | 107.72 Million USD | 51.57% |
| Ironwood Pharmaceuticals, Inc. | 471.07 Million USD | 88.925% |
| Kala Pharmaceuticals, Inc. | 55.94 Million USD | 6.749% |
| RedHill Biopharma Ltd. | 23.04 Million USD | -126.375% |
| Organogenesis Holdings Inc. | 460.02 Million USD | 88.659% |
| Guardion Health Sciences, Inc. | 11.91 Million USD | -337.76% |
| Cumberland Pharmaceuticals Inc. | 81.77 Million USD | 36.2% |
| Radius Health, Inc. | 1.71 Billion USD | 96.96% |
| Universe Pharmaceuticals INC | 53.28 Million USD | 2.091% |
| ProPhase Labs, Inc. | 91.92 Million USD | 43.245% |
| Phibro Animal Health Corporation | 982.18 Million USD | 94.688% |
| Procaps Group S.A. | 460.18 Million USD | 88.663% |
| Alvotech | 950.09 Million USD | 94.509% |
| TherapeuticsMD, Inc. | 43.3 Million USD | -20.467% |
| Viatris Inc. | 47.68 Billion USD | 99.891% |
| Aytu BioPharma, Inc. | 118.09 Million USD | 55.821% |
| SIGA Technologies, Inc. | 254.83 Million USD | 79.527% |
| Tilray Brands, Inc. | 4.33 Billion USD | 98.797% |
| Lifecore Biomedical, Inc. | 273.7 Million USD | 80.938% |
| Shineco, Inc. | 84.17 Million USD | 38.022% |
| PetIQ, Inc. | 868.22 Million USD | 93.991% |
| Regencell Bioscience Holdings Limited | 8.43 Million USD | -518.295% |
| Incannex Healthcare Limited | 17.04 Million USD | -206.054% |
| Neurocrine Biosciences, Inc. | 3.25 Billion USD | 98.395% |
| Alimera Sciences, Inc. | 153.52 Million USD | 66.016% |
| Silver Spike Investment Corp. | 88.57 Million USD | 41.098% |
| Assertio Holdings, Inc. | 286.41 Million USD | 81.784% |
| Shuttle Pharmaceuticals Holdings, Inc. | 5.95 Million USD | -776.601% |
| Petros Pharmaceuticals, Inc. | 33.79 Million USD | -54.377% |
| Clever Leaves Holdings Inc. | 31.24 Million USD | -66.991% |
| Cyclo Therapeutics, Inc. | 13.24 Million USD | -293.832% |
| Avadel Pharmaceuticals plc | 261.12 Million USD | 80.02% |
| Hempacco Co., Inc. | 18.04 Million USD | -189.158% |
| Talphera, Inc. | 20.39 Million USD | -155.813% |
| Alvotech | 950.09 Million USD | 94.509% |
| Eagle Pharmaceuticals, Inc. | 406.16 Million USD | 87.155% |
| Lantheus Holdings, Inc. | 1.65 Billion USD | 96.84% |
| Currenc Group, Inc. | 141.49 Million USD | 63.126% |
| Kamada Ltd. | 351.96 Million USD | 85.177% |
| Indivior PLC | 1.95 Billion USD | 97.326% |
| Evoke Pharma, Inc. | 7.06 Million USD | -638.101% |
| Flora Growth Corp. | 23.62 Million USD | -120.829% |
| Cyclo Therapeutics, Inc. | 13.24 Million USD | -293.832% |
| Evolus, Inc. | 188.99 Million USD | 72.395% |
| HUTCHMED (China) Limited | 1.27 Billion USD | 95.923% |
| Amphastar Pharmaceuticals, Inc. | 1.51 Billion USD | 96.551% |
| Akanda Corp. | 8.83 Million USD | -490.193% |